AstraZeneca plc (ADR) (NYSE:AZN)
The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
tmorkes
(< 20)
Submitted: 6/27/2007 7:00:08 PM :
Start Price:
$41.14
AZN Score:
+7.76
Bought it after it dropped from the Medimmune purchase. Should be back up to $60 range in a matter of months.
Recs
incansun
(66.28)
Submitted: 6/14/2007 6:43:14 PM :
Start Price:
$40.09
AZN Score:
-12.04
This stock is analogous to the titanic. Bad news when CFO leaves right after a big transaction with MedImmune.
Recs
boca7rel
(73.57)
Submitted: 5/26/2007 3:08:29 PM :
Start Price:
$41.35
AZN Score:
+7.80
cheap earnings compared to industry sector. Low debt to equity ratio
Recs
NetscribePhrmtcl
(92.11)
Submitted: 5/23/2007 9:13:57 AM :
Start Price:
$41.65
AZN Score:
+7.69
British drugmaker AstraZeneca is all set to acquire MedImmune for all-cash transaction with a total enterprise value of $15.2 billion. AstraZeneca will acquire all shares of MedImmune at a price of $58 per share, aggregating to a total consideration of $15.6 billion. This expensive transaction represents a premium of approximately 53% to Med Immune’s share price on April 11. The deal will significantly expands AstraZeneca’s product pipeline by adding 45 projects including 2 late-stage products and a blockbuster marketed monoclonal antibody, Synagis. The deal, which is expected to close in June comes at a time when AstraZeneca has already faced a series of research setbacks.
Although this acquisition may take a while to boost AstraZeneca’s earnings, but it brings a array of great new and growing products which would strengthen the company’s product portfolio. The acquisition will be fully funded in cash, bringing improved financial efficiency through balance sheet leverage. Moreover, the company hasn’t changed its previously announced $4 billion share buyback programme for 2007. AstraZeneca has ended collaboration with AtheroGenics on a heart-disease drug after a clinical trial failed to meet its goal.
AstraZeneca forecasts the transaction will boost earnings in 2009 and achieve $500 million in synergies by that year. The company in a move to provide a boost to its R&D activity has began construction of R&D plant near Boston. AstraZeneca has reaffirmed its EPS guidance for fiscal 2007 to be in the range of $3.80-$4.05. The strength of synergy between AstraZeneca and MedImmune should outwit the market in the coming fiscal.
Recs
OhioSt88
(23.82)
Submitted: 5/10/2007 11:33:14 AM :
Start Price:
$41.35
AZN Score:
+6.85
Undervalued. Continuously reports strong earnings and is developing and buying a pipeline with innovation.
Recs
bearmyx
(90.62)
Submitted: 5/4/2007 6:20:58 PM :
Start Price:
$41.90
AZN Score:
+5.83
near 52 week lows,
Recs
omoplata
(< 20)
Submitted: 4/10/2007 12:45:41 PM :
Start Price:
$41.84
AZN Score:
+1.92
Stock is undervalued.
Recs
marionvb
(32.93)
Submitted: 4/6/2007 4:50:47 PM :
Start Price:
$41.85
AZN Score:
-1.97
They may need some Levitra as some of their drugs go off patent.
Recs
pfxlovell
(45.55)
Submitted: 3/16/2007 3:41:57 PM :
Start Price:
$43.14
AZN Score:
-5.17
Looking to acquire biotechs to enhance pipeline. Solid company - great management.
Recs
flexnexus
(< 20)
Submitted: 3/15/2007 10:46:44 PM :
Start Price:
$43.55
AZN Score:
+5.59
While AZN has made a smart deal with Palatin (PTN), I'm generally bearish on big pharma. Lots of legislation is going to come about that will cost them a lot of money.
Recs
Rifino
(< 20)
Submitted: 1/26/2007 2:38:06 PM :
Start Price:
$41.44
AZN Score:
+0.71
The company is a very progressive company and has worked towards improving employee loyalty and satisfaction. It is very customer oriented and this should pay dividends over the long haul.
Recs
OldNickel
(98.26)
Submitted: 12/28/2006 11:27:09 PM :
Start Price:
$40.68
AZN Score:
-2.64
The Democrats are coming! The Democrats are coming!
Recs
Telke
(75.96)
Submitted: 12/28/2006 2:42:17 PM :
Start Price:
$40.85
AZN Score:
+2.50
Best valuation of the major drugs stocks. Note that I am not good enough to analyze the individual drugs or pipeline but this mgmnt has generated great ROE.
Recs
btarabishy
(< 20)
Submitted: 12/20/2006 3:26:54 PM :
Start Price:
$40.80
AZN Score:
+2.44
Unfairly undervalued compared to its peers. Blockbuster portfolio and heading in the right directions in its pipelines. Expect the stock to recover with strong sales in 07.
Recs
jazper292
(< 20)
Submitted: 12/20/2006 1:44:41 PM :
Start Price:
$40.80
AZN Score:
+2.47
Should bounce back
Recs
designedfor
(66.43)
Submitted: 12/14/2006 8:59:40 PM :
Start Price:
$42.81
AZN Score:
-1.85
great pipeline of anti tumor drugs
Recs
clu2000
(81.56)
Submitted: 10/26/2006 2:38:35 PM :
Start Price:
$46.57
AZN Score:
-12.19
earnings continue to rise, despite one drug not working
Recs
kumiawan
(47.55)
Submitted: 10/9/2006 12:10:53 PM :
Start Price:
$47.05
AZN Score:
-16.30
recent $4.5 billion in free cash to buy back stock and pay dividends.
Recs
manchesteruk
(< 20)
Submitted: 10/5/2006 3:23:44 AM :
Start Price:
$47.67
AZN Score:
-17.45
strong existing brands. but can they be replaced?
Recs
Rightime
(69.82)
Submitted: 9/13/2006 6:44:44 AM :
Start Price:
$47.40
AZN Score:
+20.03
AstraZeneca halted development of two new drug candidates: Galida for diabetes and Exanta for blood clotting. Nexuim may face pressure from prilosec due to cost by insurance companies. Crestor is a good play.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 101 - 120 of 123 : « Previous 1 2 3 4 5 6 7 Next »